Skip to main content
Edition No. 101 · GlobalEst. 2026
S&P 5007,438.03-1.48%Dow Jones51,763.02-1.20%Nasdaq24,598.43-2.59%FTSE 10010,881.55+0.91%DAX26,598.64+1.26%Nikkei 22559,662.02-1.32%Hang Seng23,753.84-2.84%EUR/USD1.0999-1.99%GBP/USD1.3183-1.93%Gold3,850.00-3.76%Crude Oil85.62-1.05%Bitcoin65,007.93-8.88%S&P 5007,438.03-1.48%Dow Jones51,763.02-1.20%Nasdaq24,598.43-2.59%FTSE 10010,881.55+0.91%DAX26,598.64+1.26%Nikkei 22559,662.02-1.32%Hang Seng23,753.84-2.84%EUR/USD1.0999-1.99%GBP/USD1.3183-1.93%Gold3,850.00-3.76%Crude Oil85.62-1.05%Bitcoin65,007.93-8.88%

Bechtel Medical Receives FDA Clearance for Combined Wound Care System

New device integrates negative pressure and topical oxygen therapy to simplify treatment for complex wounds.

By Planet Earth News Medicine Desk· Published 2026-11-16· 4 min read
PENN Explainer

Hear this story explained in 90 seconds.

Bechtel Medical has received 510(k) clearance from the U.S. Food and Drug Administration for its new wound care platform, Wound VOX. This device is the first of its kind to combine negative pressure wound therapy and topical oxygen therapy into a single, integrated system. The company, based in Phoenixville, Pennsylvania, aims to improve patient outcomes by streamlining the delivery of these two established treatments. Negative pressure wound therapy has served as a standard treatment for complex wounds for several decades. Topical oxygen therapy has also gained traction in recent years as a method to support healing, though it has historically faced challenges regarding reimbursement and clinical implementation. By merging these technologies, Bechtel Medical intends to reduce the operational complexity that clinicians often face when managing separate systems for a single patient. Independent research supports the potential benefits of using these two therapies together. A 2025 systematic review and meta-analysis published in the journal Advances in Wound Care examined 11 randomized controlled trials. The study reported that patients receiving a combination of negative pressure and topical oxygen therapy experienced higher rates of complete wound healing compared to those treated with negative pressure alone. The Wound VOX system offers three distinct modes of operation to provide flexibility for healthcare providers. Clinicians can choose between continuous negative pressure, intermittent negative pressure, or intermittent negative pressure combined with adjunctive topical oxygen therapy. This versatility allows for a more tailored approach to wound management based on the specific needs of the patient. John Gvodas, the founder and CEO of Bechtel Medical, noted that treating hard-to-heal wounds has traditionally required the use of multiple, separate devices. He explained that the new platform was designed to simplify this process while addressing the economic and operational barriers that have previously limited access to these advanced therapies. The company believes that integrating these functions will make it easier for medical facilities to provide high-quality care. Bechtel Medical focuses on engineering excellence and clinical insight to address unmet needs in the advanced wound care sector. The company maintains a commitment to patient safety and rigorous quality standards in the development of its medical technologies. This latest regulatory clearance marks a significant milestone in the firm's efforts to expand its product portfolio. The company has announced plans for a limited commercial release of the device scheduled for December 2026. This initial rollout will allow Bechtel Medical to begin introducing the technology to clinical settings. Further expansion is expected to follow as the company works to support clinical best practices across the healthcare industry. While the FDA clearance validates the safety and effectiveness of the device for its intended use, the company continues to emphasize the importance of ongoing clinical evaluation. The integration of these two therapies represents a shift toward more efficient, multi-modal wound care solutions. By reducing the number of devices required at the bedside, the system may also help lower the burden on nursing staff and other healthcare professionals. As the medical community looks for ways to improve healing rates for chronic and complex wounds, innovations like Wound VOX are becoming increasingly relevant. The ability to deliver combined therapies through a single interface could change how hospitals and clinics approach wound management. Bechtel Medical intends to continue its work in developing technologies that prioritize both patient outcomes and operational efficiency. Future developments in this field will likely focus on further refining the application of combined therapies in diverse clinical environments. The success of this platform will depend on its adoption by healthcare providers and its performance in real-world settings. For now, the clearance of this device provides a new option for clinicians tasked with treating some of the most challenging wound cases.

You've reached your free article limit

You've read 10 of 10 free articles this month. Subscribe to Planet Earth News Network for unlimited access to neutral, global journalism — plus puzzles, podcasts, and the weekly newsletter.

Already a subscriber? Sign in.

Ask the Author

Subscribers can ask the journalist a question about this story. Subscribe to ask.

Neutrality note

Auto-harvested from global news wires and presented neutrally by PENN.

Share this article

to vote

Comments

No comments yet — be the first to share your thoughts.

Related stories in Medicine